Gene editing has been described as “the medicine of the future” for years. The use of a bespoke CRISPR-based therapy in 2025 for an infant with a severe inherited disorder made that future far more concrete. In 2026, science is confronting the harder question: how can treatments designed around one mutation—and sometimes one patient—be produced within a safe, accessible and sustainable system?
Traditional drug development is built around large patient populations, long clinical programmes and standardized products. In rare genetic disease, even patients with the same diagnosis may carry different mutations. Personalized gene editing can therefore shrink the logic of “one drug for one disease” toward, in selected cases, “one design for one patient.”
That technological power brings serious responsibility. Off-target editing, immune responses, long-term follow-up, manufacturing quality, cost and equitable access remain central issues. Regulatory discussion in 2026 about more flexible but evidence-based pathways for personalized therapies is therefore a critical part of moving the field from laboratory success into health systems.
One of the most striking possibilities in personalized gene editing is designing a therapy for an extremely rare mutation affecting only one or a handful of patients. Confirming the variant, selecting the editing system, testing off-target effects and developing safe delivery are all part of the same chain. Alongside scientific promise, cost, regulation and long-term safety monitoring will determine how widely such therapies can be used.




